About Balaxi Pharmaceuticals Limited
Data last updated: 14 July 2026
Balaxi Pharmaceuticals Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Balaxi Overseas Private Limited. It specialises in pharmaceutical retail and distribution, a part of the broader pharmaceuticals sector. Incorporated on 28 September 1942, the company has been in operation for over 84 years.
Registered with ROC Hyderabad under CIN L25191TG1942PLC121598. Listed on NSE: BALAXI.
Capital: an authorised share capital of ₹40 Cr and a paid-up capital of ₹11.04 Cr. Formerly known as Balaxi Ventures Limited and Anandam Rubber Company Limited. It is led by directors including Ashish Maheshwari and Mangina Srinivas Rao.
Last AGM: 25 August 2025. Financial statements filed for year ended 31 March 2025. Office: Hyderabad, Telangana.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹270.17 Cr, a decline of 7.65% compared to the previous year. The net worth stands at ₹249.08 Cr (up 7.48% YoY). Total assets are valued at ₹337.03 Cr (up 8.6% YoY).
The company has a workforce of approximately 49 employees as per the latest available data. It operates as a subsidiary of Balaxi Overseas Private Limited.
The company is associated with 3 brands - Balaxi Pharmaceuticals, Anandam Rubber Company, Balaxi. As per MCA filings, the company has open charges of ₹36.44 Cr and satisfied charges of ₹34.29 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website balaxiventures.in.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressPlot No.409 H.No. 8 – 2 – 293 Maps Towers 3Rd Floor Phase – Iii Road No.81 Jubilee, Hills, Hyderabad, Telangana, India – 500096
-
IndustryPharma, Pharmaceutical Retailers & Distributors
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited has undergone 3 name changes throughout its history. The company was previously known as Balaxi Ventures Limited, Anandam Rubber Company Limited, and The Anandam Rubber Company Limited. The current legal name is Balaxi Pharmaceuticals Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Balaxi Pharmaceuticals Limited | Current |
| Balaxi Ventures Limited | Previous |
| Anandam Rubber Company Limited | Previous |
| The Anandam Rubber Company Limited | Previous |
CIN History of Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L25191TG1942PLC121598, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L25191TG1942PLC121598 | Current |
| U25191KL1942PLC000045 | Previous |
| L25191KL1942PLC000045 | Previous |
Associated Brands with Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited operates multiple associated brands including Balaxi Pharmaceuticals, Anandam Rubber Company, and Balaxi. These brands represent Balaxi Pharmaceuticals Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Agricultural operations, grain marketing, and equipment services by Balaxi. | balaxiventures.in | |
| Fabricated metal products are manufactured by Anandam Rubber Company. | anandamrubberco.com | |
| Drug distribution and storage services are provided by Balaxi. | balaxipharma.in |
Business Activity of Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details for Balaxi Pharmaceuticals Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited is audited by P Murali & Co (ICAI peer reviewed, certificate valid till 2027-03-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| P Murali & Co (ICAI peer reviewed, certificate valid till 2027-03-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited is currently managed by 6 directors, with 20 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Ashish Maheshwari
Also directs:
Balaxi Holdings Llp, Balaxi Overseas Private Limited, Balaxi Capital Holdings Private Limited and 1 more
|
Managing Director | 04 May 2017 | 9 Years 3 Months | Current |
|
Mangina Srinivas Rao
Also directs:
Droneacharya Aerial Innovations Limited, Tcc Concept Limited, Isera Lifesciences Limited and 5 more
|
Director | 15 Sep 2020 | 5 Years 11 Months | Current |
| Minoshi Maheshwari | Director | 04 May 2017 | 9 Years 3 Months | Current |
| Kunal Mahendra Bhakta | Director | 04 May 2017 | 9 Years 3 Months | Current |
|
Gandhi Gamji
Also directs:
Green Chemical Technologies (India) Private Limited
|
Director | 04 May 2017 | 9 Years 3 Months | Current |
| Akshita Surana | Director | 05 Sep 2024 | 1 Years 11 Months | Current |
Financials of Balaxi Pharmaceuticals Limited FY 2026 filings available
Balaxi Pharmaceuticals Limited reported revenue of ₹270.17 Cr (down 7.65% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹270.17 Cr | ₹292.56 Cr | ₹241.29 Cr | ₹336.43 Cr | ₹279.39 Cr | ₹231.33 Cr | ₹45.63 Cr |
| Other Income | ₹2.82 Cr | -₹3.72 Cr | -₹2.65 Cr | ₹2.64 Cr | ₹4.97 Cr | ₹2.23 Cr | ₹2.81 Cr |
| Total Income | ₹272.99 Cr | ₹288.84 Cr | ₹238.65 Cr | ₹339.07 Cr | ₹284.36 Cr | ₹233.56 Cr | ₹48.44 Cr |
| Cost of Materials Consumed | ₹150.88 Cr | ₹165.7 Cr | ₹128.68 Cr | ₹202.42 Cr | ₹195.6 Cr | ₹172.15 Cr | ₹33.58 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹38.19 Cr | ₹34.74 Cr | ₹27.38 Cr | ₹28.95 Cr | ₹12.47 Cr | ₹8.47 Cr | ₹2.1 Cr |
| Finance Costs | ₹3.9 Cr | ₹2.93 Cr | ₹1.68 Cr | ₹50 Lakh | ₹14.16 Lakh | ₹1.31 Lakh | ₹0 |
| Depreciation & Amortisation | ₹2.15 Cr | ₹1.89 Cr | ₹2.1 Cr | ₹1.75 Cr | ₹51.22 Lakh | ₹29.78 Lakh | ₹75,000 |
| Other Expenses | ₹72.58 Cr | ₹54.91 Cr | ₹38.51 Cr | ₹48.53 Cr | ₹21.12 Cr | ₹8.3 Cr | ₹3.89 Cr |
| Total Expenses | ₹267.7 Cr | ₹260.18 Cr | ₹198.34 Cr | ₹282.15 Cr | ₹229.84 Cr | ₹189.23 Cr | ₹39.57 Cr |
| Profit Before Exceptional Items & Tax | ₹5.29 Cr | ₹28.67 Cr | ₹40.31 Cr | ₹56.92 Cr | ₹54.52 Cr | ₹44.33 Cr | ₹8.87 Cr |
| Exceptional Items | ₹0 | ₹0 | -₹38.29 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹5.29 Cr | ₹28.67 Cr | ₹2.02 Cr | ₹56.92 Cr | ₹54.52 Cr | ₹44.33 Cr | ₹8.87 Cr |
| Total Tax Expense | ₹3.88 Cr | ₹3.6 Cr | ₹4.4 Cr | ₹10.96 Cr | ₹6.86 Cr | ₹6.19 Cr | ₹2.77 Cr |
| Net Profit | ₹1.42 Cr | ₹25.07 Cr | -₹2.39 Cr | ₹45.96 Cr | ₹47.66 Cr | ₹38.14 Cr | ₹6.1 Cr |
| attributable to Owners | - | - | ₹0 | ₹0 | ₹0 | ₹37.23 Cr | - |
| attributable to NCI | - | - | ₹0 | ₹0 | ₹0 | ₹0 | - |
| Other Comprehensive Income | ₹15.92 Cr | ₹2.6 Cr | -₹4.92 Cr | ₹5.78 Cr | ₹52.65 Lakh | -₹90.33 Lakh | ₹2.55 Lakh |
| Total Comprehensive Income | ₹17.34 Cr | ₹27.67 Cr | -₹7.31 Cr | ₹51.74 Cr | ₹48.18 Cr | ₹37.23 Cr | ₹6.13 Cr |
| EBITDA (computed) | ₹11.35 Cr | ₹33.5 Cr | ₹44.08 Cr | ₹59.17 Cr | ₹55.18 Cr | ₹44.64 Cr | ₹8.88 Cr |
| Basic EPS | ₹0.26 | ₹4.54 | ₹-2.32 | ₹45.81 | ₹47.66 | ₹38.14 | ₹8.12 |
| Diluted EPS | ₹0.26 | ₹4.54 | ₹-2.31 | ₹45.40 | ₹47.66 | ₹38.14 | ₹8.12 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹337.03 Cr | ₹310.34 Cr | ₹258.34 Cr | ₹239.67 Cr |
| Non-current Assets | ₹85.6 Cr | ₹67.58 Cr | ₹48.17 Cr | ₹46.16 Cr |
| Current Assets | ₹251.43 Cr | ₹242.77 Cr | ₹210.17 Cr | ₹193.51 Cr |
| Property, Plant & Equipment | ₹49.01 Cr | ₹14.24 Cr | ₹14.78 Cr | ₹16.18 Cr |
| Inventories | ₹83.48 Cr | ₹78.48 Cr | ₹82.17 Cr | ₹105.02 Cr |
| Trade Receivables | ₹136.1 Cr | ₹110.8 Cr | ₹55.71 Cr | ₹53.43 Cr |
| Cash & Equivalents | ₹14.56 Cr | ₹39.4 Cr | ₹62.29 Cr | ₹28.21 Cr |
| Equity (Net Worth) | ₹249.08 Cr | ₹231.74 Cr | ₹201.36 Cr | ₹182.88 Cr |
| Equity Share Capital | ₹11.04 Cr | ₹11.04 Cr | ₹10.9 Cr | ₹10.18 Cr |
| Borrowings (Non-current) | ₹22.35 Cr | ₹21.24 Cr | ₹0 | ₹86.97 Lakh |
| Borrowings (Current) | ₹33.44 Cr | ₹30.38 Cr | ₹17.66 Cr | ₹10.75 Cr |
| Total Debt (computed) | ₹55.79 Cr | ₹51.62 Cr | ₹17.66 Cr | ₹11.62 Cr |
| Current Liabilities | ₹62.16 Cr | ₹54.53 Cr | ₹54.2 Cr | ₹53.13 Cr |
| Total Liabilities | ₹87.95 Cr | ₹78.61 Cr | ₹56.98 Cr | ₹56.79 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹4.5 Cr | -₹35 Cr | ₹4.87 Cr | ₹6.08 Cr | ₹34.14 Cr |
| Investing Cash Flow | -₹20.78 Cr | -₹21.76 Cr | -₹1.05 Cr | -₹10.57 Cr | -₹28.45 Cr |
| Financing Cash Flow | ₹43.96 Lakh | ₹33.88 Cr | ₹30.25 Cr | ₹25.51 Cr | -₹16.27 Lakh |
| Capital Expenditure | ₹14.85 Cr | ₹1.36 Cr | ₹69.27 Lakh | ₹10.8 Cr | ₹4.75 Cr |
| Free Cash Flow (computed) | -₹19.35 Cr | -₹36.36 Cr | ₹4.17 Cr | -₹4.72 Cr | ₹29.39 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹49.84 Lakh | ₹0 |
| Net Change in Cash | -₹24.84 Cr | ₹39.4 Cr | ₹34.07 Cr | ₹21.02 Cr | ₹5.54 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹70.71 Cr | ₹72.54 Cr | ₹56.18 Cr | ₹70.74 Cr | ₹76.27 Cr | ₹73.29 Cr | ₹77.38 Cr | ₹65.62 Cr | ₹59.83 Cr | ₹60.79 Cr | ₹54.72 Cr | ₹65.96 Cr |
| Other Income | ₹2.92 Cr | ₹9.56 Lakh | ₹1.59 Cr | -₹1.78 Cr | -₹1.69 Cr | ₹3.94 Cr | -₹4.11 Cr | -₹1.85 Cr | -₹1.79 Cr | -₹13.23 Lakh | ₹27.99 Lakh | -₹1.01 Cr |
| Total Income | ₹73.63 Cr | ₹72.64 Cr | ₹57.76 Cr | ₹68.97 Cr | ₹74.57 Cr | ₹77.23 Cr | ₹73.27 Cr | ₹63.77 Cr | ₹58.05 Cr | ₹60.65 Cr | ₹55 Cr | ₹64.95 Cr |
| Cost of Materials Consumed | ₹40.55 Cr | ₹41.74 Cr | ₹29.03 Cr | ₹39.56 Cr | ₹39.56 Cr | ₹43.84 Cr | ₹44.17 Cr | ₹38.14 Cr | ₹28.88 Cr | ₹30.36 Cr | ₹29.12 Cr | ₹40.31 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹10.63 Cr | ₹10.21 Cr | ₹8.93 Cr | ₹8.41 Cr | ₹8.63 Cr | ₹9.31 Cr | ₹8.43 Cr | ₹8.1 Cr | ₹6.89 Cr | ₹7.7 Cr | ₹6.56 Cr | ₹6.89 Cr |
| Finance Costs | ₹98.99 Lakh | ₹1.02 Cr | ₹89.22 Lakh | ₹1.01 Cr | ₹72.85 Lakh | ₹1.38 Cr | ₹45.09 Lakh | ₹37.08 Lakh | ₹60.5 Lakh | ₹41.45 Lakh | ₹36.81 Lakh | ₹28.95 Lakh |
| Depreciation & Amortisation | ₹64.65 Lakh | ₹55.95 Lakh | ₹48.45 Lakh | ₹46.25 Lakh | ₹46.12 Lakh | ₹47.89 Lakh | ₹46.26 Lakh | ₹49.21 Lakh | ₹67.11 Lakh | ₹48.1 Lakh | ₹66.1 Lakh | ₹28.53 Lakh |
| Other Expenses | ₹19.41 Cr | ₹17.5 Cr | ₹17.04 Cr | ₹18.62 Cr | ₹15.53 Cr | ₹16.15 Cr | ₹14.19 Cr | ₹9.3 Cr | ₹10.59 Cr | ₹9.07 Cr | ₹8.27 Cr | ₹9.91 Cr |
| Total Expenses | ₹72.23 Cr | ₹71.03 Cr | ₹56.38 Cr | ₹68.06 Cr | ₹64.91 Cr | ₹71.16 Cr | ₹67.71 Cr | ₹56.4 Cr | ₹47.64 Cr | ₹48.02 Cr | ₹44.99 Cr | ₹57.69 Cr |
| Profit Before Exceptional Items & Tax | ₹1.4 Cr | ₹1.61 Cr | ₹1.38 Cr | ₹90.32 Lakh | ₹9.66 Cr | ₹6.07 Cr | ₹5.56 Cr | ₹7.37 Cr | ₹10.4 Cr | ₹12.63 Cr | ₹10.02 Cr | ₹7.26 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹1.09 Cr | ₹1.64 Cr | ₹5.65 Cr | -₹46.67 Cr |
| Profit Before Tax | ₹1.4 Cr | ₹1.61 Cr | ₹1.38 Cr | ₹90.32 Lakh | ₹9.66 Cr | ₹6.07 Cr | ₹5.56 Cr | ₹7.37 Cr | ₹11.49 Cr | ₹14.27 Cr | ₹15.66 Cr | -₹39.41 Cr |
| Total Tax Expense | ₹78.97 Lakh | ₹1.3 Cr | ₹1.17 Cr | ₹61.33 Lakh | ₹1.03 Cr | ₹70.64 Lakh | ₹97.34 Lakh | ₹89.45 Lakh | ₹55.98 Lakh | ₹67.94 Lakh | ₹1.23 Cr | ₹1.93 Cr |
| Net Profit | ₹61.28 Lakh | ₹30.5 Lakh | ₹20.9 Lakh | ₹28.99 Lakh | ₹8.64 Cr | ₹5.36 Cr | ₹4.59 Cr | ₹6.48 Cr | ₹10.93 Cr | ₹13.59 Cr | ₹14.43 Cr | -₹41.34 Cr |
| attributable to Owners | - | - | - | ₹0 | - | ₹0 | - | ₹0 | ₹0 | ₹13.59 Cr | ₹14.43 Cr | -₹41.34 Cr |
| attributable to NCI | - | - | - | ₹0 | - | ₹0 | - | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹8.44 Cr | ₹1.68 Cr | ₹4.72 Cr | ₹1.08 Cr | -₹41.91 Lakh | ₹2.29 Cr | ₹0 | ₹0 | -₹32.05 Lakh | -₹4.06 Cr | -₹5.67 Cr | ₹5.12 Cr |
| Total Comprehensive Income | ₹9.06 Cr | ₹1.98 Cr | ₹4.93 Cr | ₹1.37 Cr | ₹8.22 Cr | ₹7.65 Cr | ₹4.59 Cr | ₹6.48 Cr | ₹10.61 Cr | ₹9.54 Cr | ₹8.76 Cr | -₹36.22 Cr |
| EBITDA (computed) | ₹3.04 Cr | ₹3.19 Cr | ₹2.75 Cr | ₹2.37 Cr | ₹10.85 Cr | ₹7.93 Cr | ₹6.48 Cr | ₹8.24 Cr | ₹11.68 Cr | ₹13.53 Cr | ₹11.04 Cr | ₹7.83 Cr |
| Basic EPS | ₹0.11 | ₹0.06 | ₹0.04 | ₹0.05 | ₹1.56 | ₹0.97 | ₹0.84 | ₹1.17 | ₹10.41 | ₹13.29 | ₹14.10 | ₹-40.49 |
| Diluted EPS | ₹0.11 | ₹0.06 | ₹0.04 | ₹0.05 | ₹1.56 | ₹0.97 | ₹0.84 | ₹1.17 | ₹10.38 | ₹13.22 | ₹14.06 | ₹-39.93 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹80.85 Cr | ₹60.99 Cr | ₹70.2 Cr | ₹108.14 Cr | ₹101.29 Cr | ₹86.87 Cr | ₹45.63 Cr |
| Other Income | ₹9.67 Cr | ₹5.37 Cr | ₹2.4 Cr | ₹6.6 Cr | ₹2.75 Cr | ₹1.81 Cr | ₹2.81 Cr |
| Total Income | ₹90.52 Cr | ₹66.36 Cr | ₹72.59 Cr | ₹114.74 Cr | ₹104.04 Cr | ₹88.68 Cr | ₹48.44 Cr |
| Cost of Materials Consumed | ₹69.11 Cr | ₹50.94 Cr | ₹56.49 Cr | ₹82.1 Cr | ₹76.92 Cr | ₹63.33 Cr | ₹33.58 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹6 Cr | ₹4.87 Cr | ₹4.38 Cr | ₹4.84 Cr | ₹2.9 Cr | ₹1.95 Cr | ₹1.76 Cr |
| Finance Costs | ₹2.7 Cr | ₹2.06 Cr | ₹1.54 Cr | ₹45.9 Lakh | ₹6.12 Lakh | ₹1.31 Lakh | ₹0 |
| Depreciation & Amortisation | ₹70.21 Lakh | ₹45.6 Lakh | ₹51.06 Lakh | ₹51.54 Lakh | ₹25.03 Lakh | ₹8.75 Lakh | ₹75,000 |
| Other Expenses | ₹4.97 Cr | ₹2.75 Cr | ₹4.09 Cr | ₹4.38 Cr | ₹4.21 Cr | ₹2.71 Cr | ₹3.83 Cr |
| Total Expenses | ₹83.49 Cr | ₹61.07 Cr | ₹67.01 Cr | ₹92.29 Cr | ₹84.34 Cr | ₹68.08 Cr | ₹39.18 Cr |
| Profit Before Exceptional Items & Tax | ₹7.03 Cr | ₹5.29 Cr | ₹5.58 Cr | ₹22.45 Cr | ₹19.7 Cr | ₹20.6 Cr | ₹9.27 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹7.03 Cr | ₹5.29 Cr | ₹5.58 Cr | ₹22.45 Cr | ₹19.7 Cr | ₹20.6 Cr | ₹9.27 Cr |
| Total Tax Expense | ₹1.89 Cr | ₹1.69 Cr | ₹1.93 Cr | ₹6.23 Cr | ₹5.03 Cr | ₹5.46 Cr | ₹2.77 Cr |
| Net Profit | ₹5.15 Cr | ₹3.6 Cr | ₹3.65 Cr | ₹16.22 Cr | ₹14.67 Cr | ₹15.13 Cr | ₹6.5 Cr |
| attributable to Owners | - | - | - | - | ₹0 | ₹15.13 Cr | ₹0 |
| attributable to NCI | - | - | - | - | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹5.15 Cr | ₹3.6 Cr | ₹3.65 Cr | ₹16.22 Cr | ₹14.67 Cr | ₹15.13 Cr | ₹6.5 Cr |
| EBITDA (computed) | ₹10.43 Cr | ₹7.8 Cr | ₹7.63 Cr | ₹23.42 Cr | ₹20.01 Cr | ₹20.7 Cr | ₹9.27 Cr |
| Basic EPS | ₹0.93 | ₹0.65 | ₹3.55 | ₹16.17 | ₹14.67 | ₹15.13 | ₹8.64 |
| Diluted EPS | ₹0.93 | ₹0.65 | ₹3.54 | ₹16.02 | ₹14.67 | ₹15.13 | ₹8.64 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹192.17 Cr | ₹174.45 Cr | ₹154.36 Cr | ₹129.72 Cr |
| Non-current Assets | ₹121.57 Cr | ₹54.84 Cr | ₹31.46 Cr | ₹30.7 Cr |
| Current Assets | ₹70.6 Cr | ₹119.6 Cr | ₹122.9 Cr | ₹99.02 Cr |
| Property, Plant & Equipment | ₹41.37 Cr | ₹6.67 Cr | ₹7.1 Cr | ₹7.89 Cr |
| Inventories | ₹6,000 | ₹5,000 | ₹83.92 Lakh | ₹1.49 Cr |
| Trade Receivables | ₹64.2 Cr | ₹89.92 Cr | ₹76.76 Cr | ₹79.43 Cr |
| Cash & Equivalents | ₹5.33 Cr | ₹28.68 Cr | ₹44.06 Cr | ₹17.87 Cr |
| Equity (Net Worth) | ₹133 Cr | ₹127.85 Cr | ₹121.55 Cr | ₹92.11 Cr |
| Equity Share Capital | ₹11.04 Cr | ₹11.04 Cr | ₹10.9 Cr | ₹10.18 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹33.44 Cr | ₹30.38 Cr | ₹13.96 Cr | ₹10.75 Cr |
| Total Debt (computed) | ₹33.44 Cr | ₹30.38 Cr | ₹13.96 Cr | ₹10.75 Cr |
| Current Liabilities | ₹55.73 Cr | ₹43.76 Cr | ₹30.04 Cr | ₹34.83 Cr |
| Total Liabilities | ₹59.17 Cr | ₹46.59 Cr | ₹32.82 Cr | ₹37.62 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹43.87 Cr | -₹7.6 Cr | -₹1.83 Cr | -₹7.07 Cr | ₹8.89 Cr |
| Investing Cash Flow | -₹67.77 Cr | -₹24.98 Cr | ₹46.12 Lakh | -₹2.29 Cr | -₹6.87 Cr |
| Financing Cash Flow | ₹53.88 Lakh | ₹17.21 Cr | ₹27.55 Cr | ₹26.39 Cr | -₹1.64 Cr |
| Capital Expenditure | ₹35.4 Cr | ₹3.36 Lakh | ₹3.46 Lakh | ₹10.93 Lakh | ₹1.76 Cr |
| Free Cash Flow (computed) | ₹8.48 Cr | -₹7.64 Cr | -₹1.87 Cr | -₹7.18 Cr | ₹7.13 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹49.84 Lakh | ₹0 |
| Net Change in Cash | -₹23.36 Cr | -₹15.37 Cr | ₹26.19 Cr | ₹17.03 Cr | ₹37.53 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹20.24 Cr | ₹24.59 Cr | ₹19.31 Cr | ₹16.71 Cr | ₹9.65 Cr | ₹11.16 Cr | ₹21.16 Cr | ₹19.03 Cr | ₹15.9 Cr | ₹12.7 Cr | ₹16.55 Cr | ₹25.04 Cr |
| Other Income | ₹3.37 Cr | ₹1.62 Cr | ₹4.21 Cr | ₹46.22 Lakh | ₹32.09 Lakh | ₹2.92 Cr | ₹1.29 Cr | ₹84.5 Lakh | ₹16.41 Lakh | ₹1.03 Cr | ₹1.15 Cr | ₹12.58 Lakh |
| Total Income | ₹23.61 Cr | ₹26.22 Cr | ₹23.52 Cr | ₹17.17 Cr | ₹9.97 Cr | ₹14.07 Cr | ₹22.45 Cr | ₹19.87 Cr | ₹16.07 Cr | ₹13.73 Cr | ₹17.7 Cr | ₹25.17 Cr |
| Cost of Materials Consumed | ₹17.42 Cr | ₹21.02 Cr | ₹16.51 Cr | ₹14.18 Cr | ₹8.22 Cr | ₹9.31 Cr | ₹17.72 Cr | ₹15.69 Cr | ₹13.46 Cr | ₹10.34 Cr | ₹13.62 Cr | ₹19.14 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹2.3 Cr | ₹1.22 Cr | ₹1.17 Cr | ₹1.31 Cr | ₹1.34 Cr | ₹1.19 Cr | ₹1.14 Cr | ₹1.15 Cr | ₹1.26 Cr | ₹1.29 Cr | ₹1.27 Cr | ₹1.24 Cr |
| Finance Costs | ₹70.72 Lakh | ₹73.43 Lakh | ₹62.4 Lakh | ₹63.1 Lakh | ₹69.33 Lakh | ₹56.58 Lakh | ₹44.85 Lakh | ₹35.36 Lakh | ₹51.06 Lakh | ₹41.12 Lakh | ₹36.18 Lakh | ₹25.79 Lakh |
| Depreciation & Amortisation | ₹31.29 Lakh | ₹15.3 Lakh | ₹12.34 Lakh | ₹11.28 Lakh | ₹11.15 Lakh | ₹11.38 Lakh | ₹11.57 Lakh | ₹11.52 Lakh | ₹11.63 Lakh | ₹13.18 Lakh | ₹13.22 Lakh | ₹13.05 Lakh |
| Other Expenses | ₹2.46 Cr | ₹97.8 Lakh | ₹85.79 Lakh | ₹67.89 Lakh | ₹73.92 Lakh | ₹56 Lakh | ₹81.75 Lakh | ₹67.08 Lakh | ₹98.2 Lakh | ₹79.54 Lakh | ₹74.39 Lakh | ₹88.9 Lakh |
| Total Expenses | ₹23.19 Cr | ₹24.1 Cr | ₹19.28 Cr | ₹16.91 Cr | ₹11.11 Cr | ₹11.74 Cr | ₹20.24 Cr | ₹17.98 Cr | ₹16.33 Cr | ₹12.96 Cr | ₹16.13 Cr | ₹21.66 Cr |
| Profit Before Exceptional Items & Tax | ₹41.36 Lakh | ₹2.12 Cr | ₹4.24 Cr | ₹25.83 Lakh | -₹1.14 Cr | ₹2.33 Cr | ₹2.2 Cr | ₹1.89 Cr | -₹26.42 Lakh | ₹76.65 Lakh | ₹1.57 Cr | ₹3.51 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹41.36 Lakh | ₹2.12 Cr | ₹4.24 Cr | ₹25.83 Lakh | -₹1.14 Cr | ₹2.33 Cr | ₹2.2 Cr | ₹1.89 Cr | -₹26.42 Lakh | ₹76.65 Lakh | ₹1.57 Cr | ₹3.51 Cr |
| Total Tax Expense | ₹25.55 Lakh | ₹58.85 Lakh | ₹97.85 Lakh | ₹6.34 Lakh | ₹4.1 Lakh | ₹59.12 Lakh | ₹54.31 Lakh | ₹51.1 Lakh | ₹31.1 Lakh | ₹27.83 Lakh | ₹38.93 Lakh | ₹95.42 Lakh |
| Net Profit | ₹15.81 Lakh | ₹1.53 Cr | ₹3.26 Cr | ₹19.49 Lakh | -₹1.18 Cr | ₹1.74 Cr | ₹1.66 Cr | ₹1.38 Cr | -₹57.52 Lakh | ₹48.82 Lakh | ₹1.18 Cr | ₹2.55 Cr |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹15.81 Lakh | ₹1.53 Cr | ₹3.26 Cr | ₹19.49 Lakh | -₹1.18 Cr | ₹1.74 Cr | ₹1.66 Cr | ₹1.38 Cr | -₹57.52 Lakh | ₹48.82 Lakh | ₹1.18 Cr | ₹2.55 Cr |
| EBITDA (computed) | ₹1.43 Cr | ₹3.01 Cr | ₹4.99 Cr | ₹1 Cr | -₹33.27 Lakh | ₹3.01 Cr | ₹2.77 Cr | ₹2.36 Cr | ₹36.27 Lakh | ₹1.31 Cr | ₹2.07 Cr | ₹3.9 Cr |
| Basic EPS | ₹0.03 | ₹0.28 | ₹0.59 | ₹0.04 | ₹-0.21 | ₹0.32 | ₹0.30 | ₹0.25 | ₹-0.55 | ₹0.48 | ₹1.16 | ₹2.50 |
| Diluted EPS | ₹0.03 | ₹0.28 | ₹0.59 | ₹0.04 | ₹-0.21 | ₹0.32 | ₹0.30 | ₹0.25 | ₹-0.55 | ₹0.47 | ₹1.15 | ₹2.47 |
Shareholding Pattern of Balaxi Pharmaceuticals Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 65.99%, foreign institutional investors hold 0.00%, domestic institutional investors hold 2.56%, retail and other public shareholders hold 31.45% of Balaxi Pharmaceuticals Limited. The company had 15,176 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% |
| Public | 34.01% | 34.01% | 34.01% | 34.01% | 34.01% | 34.01% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 65.99% | 65.99% | 66.86% | 71.57% | 72.86% | 72.86% | 72.86% | 73.24% | 73.24% | 54.94% | 54.94% |
| Public | 34.01% | 34.01% | 33.14% | 28.43% | 27.14% | 27.14% | 27.13% | 26.76% | 26.76% | 45.06% | 45.06% |
| Promoter change (YoY, %pts) | +0.00 | -0.87 | -4.71 | -1.29 | +0.00 | +0.00 | -0.38 | +0.00 | +18.30 | +0.00 | - |
Board & Governance of Balaxi Pharmaceuticals Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Balaxi Pharmaceuticals Limited has 6 directors - 4 independent and 1 executive. The board is chaired by ASHISH MAHESHWARI.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| ASHISH MAHESHWARI | Executive Director · MD · Chairperson | 2017-05-04 | 1 |
| MINOSHI MAHESHWARI | Non-Executive - Non Independent Director | 2018-02-12 | 1 |
| KUNAL MAHENDRA BHAKTA | Non-Executive - Independent Director | 2017-05-04 | 1 |
| GANDHI GAMJI | Non-Executive - Independent Director | 2017-05-04 | 1 |
| MANGINA SRINIVAS RAO | Non-Executive - Independent Director | 2020-09-15 | 7 |
| AKSHITA SURANA | Non-Executive - Independent Director | 2024-09-05 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | KUNAL MAHENDRA BHAKTA (Chairperson), GANDHI GAMJI, ASHISH MAHESHWARI, MANGINA SRINIVAS RAO |
| Nomination and remuneration committee | KUNAL MAHENDRA BHAKTA (Chairperson), GANDHI GAMJI, MINOSHI MAHESHWARI |
| Stakeholders Relationship Committee | KUNAL MAHENDRA BHAKTA (Chairperson), GANDHI GAMJI, MINOSHI MAHESHWARI |
| Risk Management Committee | ASHISH MAHESHWARI (Chairperson), GANDHI GAMJI, AMOL ANAND MANTRI |
| Corporate Social Responsibility Committee | MINOSHI MAHESHWARI (Chairperson), ASHISH MAHESHWARI, GANDHI GAMJI |
Charges & Borrowings of Balaxi Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Nov 2025 | Axis Bank Limited | ₹1.44 Cr | Open |
| 16 Sep 2024 | Yes Bank Limited | ₹35 Cr | Open |
| 26 Jul 2022 | Others | ₹31 Cr | Satisfied |
| 29 Jun 2021 | Yes Bank Limited | ₹1 Cr | Satisfied |
| 23 Jun 2020 | Others | ₹21 Lakh | Satisfied |
Total charge records: 10 View all charges
Employees and EPFO Compliance at Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited has a workforce of 49 employees as of Apr 03, 2024.
Employee and EPFO history for Balaxi Pharmaceuticals Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Balaxi Pharmaceuticals Limited
GST registrations and filing compliance for Balaxi Pharmaceuticals Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Balaxi Pharmaceuticals Limited
Credit ratings, litigation, and regulatory alerts for Balaxi Pharmaceuticals Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Balaxi Pharmaceuticals Limited
MSME payment history for Balaxi Pharmaceuticals Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Balaxi Pharmaceuticals Limited
Corporate group structure for Balaxi Pharmaceuticals Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Balaxi Pharmaceuticals Limited
MCA filings and documents for Balaxi Pharmaceuticals Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Balaxi Pharmaceuticals Limited
Recent News on Balaxi Pharmaceuticals Limited
Frequently Asked Questions about Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 28 September 1942 (84+ years old) and is registered under CIN L25191TG1942PLC121598. Listed on NSE: BALAXI. The company has 49 employees.
Balaxi Pharmaceuticals Limited reported revenue of ₹270.17 Cr for FY 2026 (down 7.65% YoY) based on consolidated NSE filings.
The current directors of Balaxi Pharmaceuticals Limited are:
- Ashish Maheshwari - Managing Director
- Mangina Srinivas Rao - Director
- Minoshi Maheshwari - Director
- Kunal Mahendra Bhakta - Director
- Gandhi Gamji - Director
- Akshita Surana - Director
The primary industry of Balaxi Pharmaceuticals Limited is pharma. The company specifically operates in pharmaceutical retailers and distributors. The company is currently active in this sector.
Yes. Balaxi Pharmaceuticals Limited is listed on NSE with symbol BALAXI.
Balaxi Pharmaceuticals Limited can be reached at the registered office: Plot No.409 H.No. 8 – 2 – 293 Maps Towers 3Rd Floor Phase – Iii Road No.81 Jubilee, Hills, Hyderabad, Telangana, India – 500096, or through the website balaxiventures.in.